Braveheart Bio, Inc. (BRVE) income statement
BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.53−0.25 (-1.33%)
Close on Nov 18, 2026Market cap $1.67BP/E –Yield –
Braveheart Bio, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 21.57
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 727.5%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.35
- Dividend yield
- –
See a number that looks wrong?